Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, continues to lead the research in HER2-positive breast cancer. In her latest study, published in Journal of Clinical Oncology (2024), she and her colleagues evaluated the efficacy of trastuzumab emtansine (T-DM1) in preventing recurrence in stage 1 HER2-positive breast cancer.
The findings showed that 97% of patients treated with T-DM1 after surgery remained free of invasive cancer after five years, reinforcing the potential of antibody-drug conjugates (ADCs) as a highly effective adjuvant therapy in early-stage breast cancer. Dr. Tolaney also emphasizes the need for biomarker research to guide treatment decisions, ensuring more precise, personalized therapy strategies for HER2-positive patients.
Through her commitment to advancing targeted treatments, Dr. Tolaney continues to shape the future of breast cancer care, improving outcomes and treatment precision.
Read more:https://lnkd.in/d4SdzQqr
